The next major breakthrough in Immuno-oncology
With a proprietary human synthetic chromosome (hSynC) as a carrier for antitumoral factors (OncoSynC) introduced into the patient’s own T-cells, CarryGenes’ Cromo-T will create a state of long-term vaccination against the patient’s tumor using immune cells loaded with an enhanced tumor-killing capacity. 

With a passion for science CarryGenes merges technologies as well as expertise in immunotherapy and chromosome bioengineering to produce a novel therapeutic with advanced safety mechanisms

With a lifelong passion for science and improving human health, the team has a joint ambition to use their knowledge to improve human health. Today there are no similar solutions to fight cancer.

CarryGenes

Org chart

Teams

Offices